# US 2025/0084148 A1 · Compositions and methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084148 A1
- Document ID: US20250084148A1
- Status: Published application
- Kind: A1
- Application number: 18/956,102
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2017-02-23
- Assignees: Board of Regents of the University of Nebraska
- Applicants: Board of Regents of the University of Nebraska
- Inventors: Hamid Band; Vimla Band; Fany Iseka; Bhopal Mohapatra; Matthew Storck
- Web page: https://patentgrep.com/patent/US20250084148A1

## CPC

- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- C07K 14/70521: {CD28, CD152}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4258: {Gangliosides, e.g. GM2, GD2 or GD3}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/3061: {Blood cells}
- C07K 16/3084: {against tumour-associated gangliosides}
- C07K 16/32: against translation products of oncogenes
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 9/104: {Aminoacyltransferases (2.3.2)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 203/02: Aminoacyltransferases (2.3.2)
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/03: containing a transmembrane segment
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods and compositions for treating cancer, particularly improved CAR-T methods, are disclosed.

## Claims

### Claim 1

A method of treating and/or inhibiting cancer in a subject, said method comprising administering to said subject a therapeutically effective amount of T cells that express a chimeric antigen receptor,
wherein the expression of CBL and/or CBL-B is inhibited in said T cells, and
wherein said chimeric antigen receptor comprises an antibody or fragment thereof immunologically specific for a tumor specific surface antigen of said cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T cells express at least one inhibitory nucleic acid molecule for CBL and/or CBL-B, thereby inhibiting expression of CBL and/or CBL-B.

### Claim 3 (depends on 2)

The method of claim 2, wherein said T cells express inhibitory nucleic acid molecules for CBL and CBL-B.

### Claim 4 (depends on 2)

The method of claim 2, wherein said inhibitory nucleic acid molecule is a siRNA or a shRNA.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CBL and/or CBL-B gene is inactivated or deleted.

### Claim 6 (depends on 5)

The method of claim 5, wherein said CBL and/or CBL-B gene is inactivated or deleted by CRISPR editing.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cancer is a solid tumor.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cancer is a hematological cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein said T cells are autologous for the subject being treated.

### Claim 10 (depends on 1)

The method of claim 1, wherein said method further comprises obtaining T cells from said subject and transducing the obtained T cells with a nucleic acid molecule encoding said chimeric antigen receptor and at least one inhibitory nucleic acid molecule for CBL or CBL-B.

### Claim 11

An isolated T cell comprising a nucleic acid molecule encoding a chimeric antigen receptor, and wherein the expression of CBL and/or CBL-B is inhibited in said T cell.

### Claim 12 (depends on 11)

The isolated T cell of claim 11, wherein said T cells comprises at least one inhibitory nucleic acid molecule for CBL and/or CBL-B.

### Claim 13 (depends on 12)

The isolated T cells of claim 12, wherein said T cells comprise inhibitory nucleic acid molecules for CBL and CBL-B.

### Claim 14 (depends on 12)

The isolated T cells of claim 12, wherein said inhibitory nucleic acid molecule is a siRNA or a shRNA.

### Claim 15 (depends on 11)

The isolated T cell of claim 11, wherein the CBL and/or CBL-B gene is inactivated or deleted.

### Claim 16 (depends on 11)

A composition comprising the isolated T cells of claim 11 and at least one pharmaceutically acceptable carrier.

### Claim 17

A method of increasing the efficacy of a chimeric antigen receptor T-cell therapy comprising reducing the expression of CBL and/or CBL-B in the chimeric antigen receptor T-cells prior to administration of the T cells to a subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein the expression of CBL and/or CBL-B is reduced by inactivating or deleting the CBL and/or CBL-B gene.

### Claim 19 (depends on 18)

The method of claim 18, wherein the CBL and/or CBL-B gene are inactivated or deleted by CRISPR editing.

### Claim 20 (depends on 17)

The method of claim 17, wherein the expression of CBL and/or CBL-B is reduced by delivering an inhibitory nucleic acid molecule for CBL and/or CBL-B to the chimeric antigen receptor T-cells.

### Claim 21

A vector comprising i) a nucleic acid sequence encoding a chimeric antigen receptor and ii) a nucleic acid sequence encoding at least one inhibitory nucleic acid molecule for CBL or CBL-B.

### Claim 22 (depends on 21)

The vector of claim 21, wherein said vector comprises a nucleic acid sequence encoding an inhibitory nucleic acid molecule for CBL and an inhibitory nucleic acid molecule for CBL-B.

### Claim 23 (depends on 21)

The vector of claim 21, wherein said inhibitory nucleic acid molecule is a siRNA or a shRNA.

### Claim 24

A kit comprising a first vector comprising a nucleic acid sequence encoding a chimeric antigen receptor and a second vector comprising a nucleic acid sequence encoding at least one inhibitory nucleic acid molecule for CBL or CBL-B.

### Claim 25 (depends on 24)

The kit of claim 24, wherein said second vector comprises a nucleic acid sequence encoding an inhibitory nucleic acid molecule for CBL and an inhibitory nucleic acid molecule for CBL-B.

### Claim 26 (depends on 24)

The kit of claim 24, wherein said inhibitory nucleic acid molecule is a siRNA or a shRNA.
